Skip to content

Change website language

Annual reports

These reports provide a comprehensive yearly summary of the samples analysed by WEDINOS/Philtre, highlighting key trends, statistical data, and public health implications. These reports offer a broad overview of substance use and market trends and informs policy and harm reduction strategies.

  • WEDINOS Philtre annual report October 2014 – September 2015

    This report dated October 2014 provides a comprehensive yearly summary of the samples analysed by WEDINOS/Philtre, highlighting key trends, statistical data, and public health implications. This report offers a broad […]

  • WEDINOS Philtre annual report October 2013 – September 2014

    This report dated October 2013 provides a comprehensive yearly summary of the samples analysed by WEDINOS/Philtre, highlighting key trends, statistical data, and public health implications. This report offers a broad […]

  • WEDINOS Nitazenes within the illicit benzodiazepine market

    This WEDINOS report highlights a concerning trend in the UK’s illicit drug market: the infiltration of highly potent synthetic opioids, specifically nitazenes, into substances sold as benzodiazepines. The report underscores […]

  • WEDINOS MDMA: ecstasy and apathy

    This WEDINOS report highlights the increasing potency and variability of MDMA (ecstasy) tablets in the UK. The report emphasizes that the strength of MDMA tablets can vary widely, even within […]

  • WEDINOS winter watchlist 2015

    This WEDINOS report highlights emerging concerns in the UK’s illicit drug market, particularly the prevalence of Synthetic Cannabinoid Receptor Agonists (SCRAs), synthetic opioids, and misrepresented MDMA samples.

  • WEDINOS Philtre annual report 2022 to 2023

    WEDINOS analysis again highlights concerns of substance substitution within the UK drug market. Over the past year, Bromazolam was the most commonly identified benzodiazepine, and most often purchased with the […]